Aleix Prat

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8319241/publications.pdf

Version: 2024-02-01

319 papers	33,413 citations	9756 73 h-index	4323 173 g-index
334 all docs	334 docs citations	334 times ranked	38079 citing authors

#	Article	IF	Citations
1	Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 2022, 114, 467-470.	3.0	13
2	Gene expression profiles of breast cancer metastasis according to organ site. Molecular Oncology, 2022, 16, 69-87.	2.1	24
3	HighFGFR1â€“4mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. Clinical Cancer Research, 2022, 28, 137-149.	3.2	12
4	Biomarkers of immunotherapy response in breast cancer beyond PD-L1. Breast Cancer Research and Treatment, 2022, 191, 39-49.	1.1	11
5	Time-Dependent COVID-19 Mortality in Patients With Cancer. JAMA Oncology, 2022, 8, 114.	3.4	50
6	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. EBioMedicine, 2022, 75, 103801.	2.7	47
7	Abstract P1-18-03: Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A. Cancer Research, 2022, 82, P1-18-03-P1-18-03.	0.4	3
8	Abstract P2-15-01: Conversion from luminal to normal intrinsic subtype by PAM50 after neoadjuvant endocrine therapy is associate with biomarkers of good prognosis in luminal breast cancer. Cancer Research, 2022, 82, P2-15-01-P2-15-01.	0.4	0
9	Abstract P4-10-04: Health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative, luminal B breast cancer patients treated with ribociclib plus letrozole or chemotherapy. Cancer Research, 2022, 82, P4-10-04-P4-10-04.	0.4	2
10	Abstract PD13-04: Activity of patritumab deruxtecan, a HER3-directed antibody drug conjugate, in early breast cancer according to ERBB3 expression: Interim analysis results of a window-of-opportunity study (SOLTI-1805 TOT-HER3). Cancer Research, 2022, 82, PD13-04-PD13-04.	0.4	2
11	Abstract P4-10-01: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05). Cancer Research, 2022, 82, P4-10-01-P4-10-01.	0.4	1
12	Abstract TF2-3: Molecular heterogeneity in HER2+ breast cancer - can outcomes be predicted?. Cancer Research, 2022, 82, TF2-3-TF2-3.	0.4	0
13	Abstract PD15-01: Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial. Cancer Research, 2022, 82, PD15-01-PD15-01.	0.4	3
14	Abstract OT2-11-07: Solti-1905. Elacestrant in preoperative setting, a window of opportunity study (ELIPSE trial). Cancer Research, 2022, 82, OT2-11-07-OT2-11-07.	0.4	2
15	Abstract P4-06-08: Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer specialists - 1st results of the PROCURE project. Cancer Research, 2022, 82, P4-06-08-P4-06-08.	0.4	0
16	Abstract OT1-17-01: Solti-1716. Targeting with pembrolizumab + paclitaxel non-luminal by PAM50 hormone receptor-positive/HER2-negative advanced/metastatic breast cancer patients who have progressed on or after CDK4/6 inhibitor treatment (TATEN trial). Cancer Research, 2022, 82, OT1-17-01-OT1-17-01.	0.4	1
17	Abstract PD8-03: Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303) Tj ETQq1 1 0.784314 rgBT /Overlock Cancer Research, 2022, 82, PD8-03-PD8-03.	0.4	0
18	Abstract OT2-27-01: Solti-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC). Cancer Research, 2022, 82, OT2-27-01-OT2-27-01.	0.4	1

#	Article	IF	Citations
19	Abstract OT1-12-01: Solti-1804 HER2-PREDICT: Translational study of tumor samples from breast cancer patients treated with trastuzumab deruxtecan in the metastatic setting. Cancer Research, 2022, 82, OT1-12-01-OT1-12-01.	0.4	0
20	Abstract GS2-00: Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2â^' advanced breast cancer. Cancer Research, 2022, 82, GS2-00-GS2-00.	0.4	8
21	Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies. Cancer Research, 2022, 82, PD2-05-PD2-05.	0.4	2
22	Abstract P2-14-13: Talimogene laherparepvec (T-VEC) + atezolizumab combination in early breast cancer (SOLTI-1503 PROMETEO): Safety and efficacy interim analysis. Cancer Research, 2022, 82, P2-14-13-P2-14-13.	0.4	1
23	Abstract P1-07-02: Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC). Cancer Research, 2022, 82, P1-07-02-P1-07-02.	0.4	1
24	Abstract OT2-19-03: Solti-1801. Analysis of the efficacy of CDK4/6 inhibitors in combination with hormonal treatment in luminal breast cancer in relation to the intrinsic subtype and markers of immunity (CDK-predict). Cancer Research, 2022, 82, OT2-19-03-OT2-19-03.	0.4	1
25	Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?. Cancer Treatment Reviews, 2022, 106, 102392.	3.4	11
26	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. European Journal of Cancer, 2022, 170, 10-16.	1.3	11
27	Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Science Advances, 2022, 8, .	4.7	21
28	Vaccination against SARS-CoV-2 protects from morbidity, mortalityÂand sequelae from COVID19 in patients with cancer. European Journal of Cancer, 2022, 171, 64-74.	1.3	19
29	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. Lancet Oncology, The, 2022, 23, 865-875.	5.1	50
30	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine, 2022, 387, 9-20.	13.9	854
31	Prevalence of incidental pathogenic germline variants detected in cfDNA in patients with oncogene-driven non-small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 10569-10569.	0.8	1
32	Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.. Journal of Clinical Oncology, 2022, 40, 1028-1028.	0.8	9
33	Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.. Journal of Clinical Oncology, 2022, 40, 518-518.	0.8	4
34	Circulating tumor DNA profile in pancreatic ductal adenocarcinoma (PDAC) and potential targeted therapy.. Journal of Clinical Oncology, 2022, 40, 4152-4152.	0.8	0
35	Consensus on the utility of breast cancer multigene signatures in routine clinical practice: Results of the PROCURE Project.. Journal of Clinical Oncology, 2022, 40, e13639-e13639.	0.8	0
36	Diversity, inclusion, and patient (pt)-centricity in the randomized, double-blind, phase III ASTEFANIA study of ado-trastuzumab emtansine (T-DM1) Â± atezolizumab in pts with HER2-positive early breast cancer (EBC) with residual invasive disease after preoperative chemotherapy and anti-HER2 therapy.. Journal of Clinical Oncology, 2022, 40, e12504-e12504.	0.8	1

#	Article	IF	Citations
37	PBRM1 genomic alterations as a predictive biomarker to immune checkpoint inhibitors (ICI) and/or anti-angiogenic therapies (anti-VEGF) in metastatic renal cell carcinoma (mRCC): A systematic review and meta-analysis.. Journal of Clinical Oncology, 2022, 40, e16515-e16515.	0.8	0
38	14-gene immunoglobulin (IGG) and proliferation signatures and association with overall survival across cancer-types.. Journal of Clinical Oncology, 2022, 40, 2636-2636.	0.8	6
39	The FLARE score, circulating neutrophils, and association with COVID-19 outcomes in patients with solid tumors.. Journal of Clinical Oncology, 2022, 40, 2551-2551.	0.8	0
40	Estrogen receptor Î² and TMPRSS2-ERG expression association with clinical outcomes in metastatic hormone-sensitive prostate cancer.. Journal of Clinical Oncology, 2022, 40, 5077-5077.	0.8	0
41	De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. Clinical Cancer Research, 2022, 28, 4995-5003.	3.2	6
42	Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188487.	3.3	16
43	Multiplex RNAâ€based detection of clinically relevant MET alterations in advanced nonâ€small cell lung cancer. Molecular Oncology, 2021, 15, 350-363.	2.1	17
44	Molecular profiling of longâ€term responders to immune checkpoint inhibitors in advanced nonâ€small cell lung cancer. Molecular Oncology, 2021, 15, 887-900.	2.1	24
45	The BRCA1 Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms. Cancer Research, 2021, 81, 1540-1551.	0.4	6
46	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110422.	1.4	4
47	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. Npj Breast Cancer, 2021, 7, 1.	2.3	331
48	A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. Breast Cancer Research, 2021, 23, 8.	2.2	15
49	Abstract OT-09-08: Solti-1502 aRIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer. , 2021, , .		1
50	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptorâ€“Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Antiâ€“HER2-Based Therapy. Clinical Cancer Research, 2021, 27, 3116-3125.	3.2	9
51	Abstract GS1-04: Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies. Cancer Research, 2021, 81, GS1-04-GS1-04.	0.4	3
52	Abstract OT-13-04: Solti-1716. Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer patients who have progressed on or after CDK 4/6 inhibitor treatment (TATEN trial). , 2021, , .		3
53	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. Npj Breast Cancer, 2021, 7, 12.	2.3	9
54	Abstract OT-03-07: Solti-1804 HER2-PREDICT: A biomarker research study of DS8201-A-U301 -U302 and -U303 trials. , 2021, , .		1

#	Article	IF	Citations
55	Development and validation for research assessment of Oncotype DXÂ® Breast Recurrence Score, EndoPredictÂ® and ProsignaÂ®. Npj Breast Cancer, 2021, 7, 15.	2.3	11
56	Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. Npj Breast Cancer, 2021, 7, 8.	2.3	14
57	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, The, 2021, 22, 212-222.	5.1	169
58	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers, 2021, 13, 1458.	1.7	17
59	Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. Npj Precision Oncology, 2021, 5, 23.	2.3	26
60	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. , 2021, 9, e002277.		30
61	RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. Breast Cancer Research, 2021, 23, 42.	2.2	11
62	Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncology, The, 2021, 22, 489-498.	5.1	157
63	SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. Frontiers in Oncology, 2021, 11, 638482.	1.3	16
64	A phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease.. Journal of Clinical Oncology, 2021, 39, 1057-1057.	0.8	1
65	Pembrolizumab plus eribulin in hormone-receptorâ€“positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase â…¡ trial. European Journal of Cancer, 2021, 148, 382-394.	1.3	22
66	Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. European Journal of Cancer, 2021, 148, 134-145.	1.3	10
67	Determinants of enhanced vulnerability to Covid-19 in U.K. cancer patients: Results from the OnCovid study.. Journal of Clinical Oncology, 2021, 39, 1574-1574.	0.8	1
68	Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. Journal of Clinical Oncology, 2021, 39, 1458-1467.	0.8	73
69	Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncology, The, 2021, 22, 858-871.	5.1	60
70	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. European Journal of Cancer, 2021, 149, 134-152.	1.3	41
71	Current and Future Management of HER2-Positive Metastatic Breast Cancer. JCO Oncology Practice, 2021, 17, 594-604.	1.4	102
72	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. Npj Breast Cancer, 2021, 7, 73.	2.3	2

#	Article	IF	Citations
73	Identification of cell surface targets for CAR-T cell therapies and antibodyâ€“drug conjugates in breast cancer. ESMO Open, 2021, 6, 100102.	2.0	24
74	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. European Journal of Cancer, 2021, 150, 190-202.	1.3	37
75	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. EBioMedicine, 2021, 69, 103451.	2.7	7
76	Abstract 1075: AXL is a potential druggable target in trastuzumab resistance in HER2+ breast cancer patients. , 2021, , .		0
77	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. European Journal of Cancer, 2021, 153, 133-141.	1.3	20
78	Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. Annals of Hematology, 2021, 100, 2997-3005.	0.8	2
79	Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMxÂ® Digital Spatial Profiler. Cancers, 2021, 13, 4456.	1.7	50
80	Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer. Frontiers in Oncology, 2021, 11, 710596.	1.3	5
81	Dissecting the biological heterogeneity of HER2-positive breast cancer. Breast, 2021, 59, 339-350.	0.9	41
82	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of Oncology, 2021, 32, 1216-1235.	0.6	354
83	Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes. Cancers, 2021, 13, 4960.	1.7	7
84	Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 313.	3.5	6
85	De novo metastatic breast cancer arising in young women: review of the current evidence. Clinical Breast Cancer, 2021, , .	1.1	6
86	First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. Frontiers in Oncology, 2021, 11, 744112.	1.3	3
87	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncology, The, 2021, 22, 1669-1680.	5.1	73
88	Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. Frontiers in Immunology, 2021, 12, 792609.	2.2	3
89	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. Npj Breast Cancer, 2021, 7, 145.	2.3	9
90	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110534.	1.4	5

#	Article	IF	Citations
91	Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in tripleâ€negative early breast cancer: Primary translational analysis of the WSGâ€ADAPTâ€TN trial. International Journal of Cancer, 2020, 146, 262-271.	2.3	27
92	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. Journal of the National Cancer Institute, 2020, 112, 46-54.	3.0	97
93	Standardized versus research-based PAM50 intrinsic subtyping of breast cancer. Clinical and Translational Oncology, 2020, 22, 953-955.	1.2	11
94	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clinical Cancer Research, 2020, 26, 738-745.	3.2	31
95	Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 33-43.	5.1	105
96	5th ESO-ESMO international consensus guidelines for advanced breastÂcancer (ABC 5). Annals of Oncology, 2020, 31, 1623-1649.	0.6	761
97	Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. Cancers, 2020, 12, 1841.	1.7	58
98	ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. Cancers, 2020, 12, 1902.	1.7	29
99	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Research, 2020, 22, 120.	2.2	60
100	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. Cancer Discovery, 2020, 10, 1465-1474.	7.7	151
101	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Lancet Oncology, The, 2020, 21, 1455-1464.	5.1	52
102	A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptorâ€“positive HER2-negative Breast Cancer. Clinical Cancer Research, 2020, 26, 6141-6148.	3.2	6
103	PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. Clinical Cancer Research, 2020, 26, 5843-5851.	3.2	17
104	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. Clinical Cancer Research, 2020, 26, 5820-5829.	3.2	68
105	Implementing preoperative endocrine therapy in breast cancer. Lancet Oncology, The, 2020, 21, 1390-1392.	5.1	0
106	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Research, 2020, 22, 45.	2.2	175
107	Overall Survival of CDK4/6-Inhibitorâ€“Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2020, 112, 1089-1097.	3.0	59
108	Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 4688-4698.	3.2	30

#	Article	IF	Citations
109	SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. Future Oncology, 2020, 16, 1801-1813.	1.1	8
110	The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver. Oncogene, 2020, 39, 5455-5467.	2.6	12
111	What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?. Clinical Cancer Research, 2020, 26, 2783-2788.	3.2	27
112	Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. Cells, 2020, 9, 203.	1.8	15
113	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2020, 84, 101965.	3.4	92
114	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. Nature Communications, 2020, 11, 385.	5.8	67
115	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. Clinical Cancer Research, 2020, 26, 3720-3731.	3.2	21
116	FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. Journal of Clinical Investigation, 2020, 130, 4871-4887.	3.9	49
117	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2â€“) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.. Journal of Clinical Oncology, 2020, 38, 1006-1006.	0.8	52
118	A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC).. Journal of Clinical Oncology, 2020, 38, 1011-1011.	0.8	4
119	Early safety from a phase I, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into liver tumors in combination with pembrolizumab (pem).. Journal of Clinical Oncology, 2020, 38, 3015-3015.	0.8	5
120	DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature.. Journal of Clinical Oncology, 2020, 38, 5012-5012.	0.8	48
121	Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial.. Journal of Clinical Oncology, 2020, 38, 503-503.	0.8	22
122	A phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole (ANA) in postmenopausal women and men with estrogen receptor (ER)+/human epidermal growth factor 2 (HER2)- primary breast cancer (BC): CheckMate 7A8.. Journal of Clinical Oncology, 2020, 38, TPS1105-TPS1105.	0.8	4
123	Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients. Cancers, 2020, 12, 1124.	1.7	5
124	Response to immunotherapy, platinum-based chemotherapy or their combination in metastatic urothelial carcinoma (MUC) with or without FGFR-3 alterations: Single cohort experience.. Journal of Clinical Oncology, 2020, 38, 560-560.	0.8	0
125	Association of high plasma glutamine levels with outcome in metastatic castration-resistant prostate (mCRPC) patients treated with taxanes.. Journal of Clinical Oncology, 2020, 38, 164-164.	0.8	0
126	Association of neuroendocrine (NE) mRNA expression profiling in hormone-sensitive tumors samples with adverse clinical outcome in castration-resistant prostate cancer (CRPC) patients.. Journal of Clinical Oncology, 2020, 38, 165-165.	0.8	0

#	Article	IF	Citations
127	806â€...Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer. , 2020, , .		0
128	The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. Molecular Cancer Research, 2019, 17, 2063-2076.	1.5	20
129	Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response. European Journal of Radiology, 2019, 117, 132-139.	1.2	10
130	Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial. Annals of Oncology, 2019, 30, v81.	0.6	2
131	Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. European Journal of Cancer, 2019, 120, 54-64.	1.3	18
132	PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution. Frontiers in Oncology, 2019, 9, 707.	1.3	14
133	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncology, The, 2019, 20, 1360-1369.	5.1	131
134	Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. Breast Cancer Research, 2019, 21, 108.	2.2	21
135	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Clinical Cancer Research, 2019, 25, 2975-2987.	3.2	76
136	Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. Cancer Research, 2019, 79, 4258-4270.	0.4	17
137	Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. Breast Cancer Research and Treatment, 2019, 177, 103-114.	1.1	34
138	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. Frontiers in Oncology, 2019, 9, 303.	1.3	8
139	A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. Annals of Oncology, 2019, 30, 927-933.	0.6	37
140	Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. , 2019, 7, 90.		80
141	Ability of a urine gene expression classifier to reduce the number of follow-up cystoscopies in bladder cancer patients. Translational Research, 2019, 208, 73-84.	2.2	5
142	The influence of treatment sequence in the prognostic value of TMPRSS2â€ERG as biomarker of taxane resistance in castrationâ€resistant prostate cancer. International Journal of Cancer, 2019, 145, 1970-1981.	2.3	13
143	De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. Annals of Oncology, 2019, 30, 921-926.	0.6	64
144	Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. Oncologist, 2019, 24, 893-900.	1.9	25

#	Article	IF	Citations
145	Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. Frontiers in Oncology, 2019, 9, 1178.	1.3	10
146	Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis. JCO Precision Oncology, 2019, 3, 1-6.	1.5	14
147	SEOM clinical guidelines in early stage breast cancer (2018). Clinical and Translational Oncology, 2019, 21, 18-30.	1.2	48
148	Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. BMC Medicine, 2019, 17, 8.	2.3	28
149	Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.. Journal of Clinical Oncology, 2019, 37, 1050-1050.	0.8	1
150	PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.. Journal of Clinical Oncology, 2019, 37, 544-544.	0.8	6
151	Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.. Journal of Clinical Oncology, 2019, 37, 571-571.	0.8	6
152	On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.. Journal of Clinical Oncology, 2019, 37, 574-574.	0.8	8
153	Prognostic value of PAM50 in residual breast cancer following neoadjuvant endocrine therapy (NET): A retrospective analysis with long follow-up.. Journal of Clinical Oncology, 2019, 37, 575-575.	0.8	1
154	DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.. Journal of Clinical Oncology, 2019, 37, TPS4588-TPS4588.	0.8	5
155	Cell plasticity associated to taxane-resistance in preclinical cell models and in circulating tumor cells from metastatic castration-resistant prostate cancer patients.. Journal of Clinical Oncology, 2019, 37, 238-238.	0.8	1
156	ARV7 and ARFL mRNA in blood to predict androgen receptor inhibitors and docetaxel response in castration-resistant prostate cancer patients.. Journal of Clinical Oncology, 2019, 37, 207-207.	0.8	0
157	The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as a biomarker of taxane resistance in castration-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, 235-235.	0.8	0
158	Coamplification of miR-4728 protects HER2 -amplified breast cancers from targeted therapy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2594-E2603.	3.3	23
159	MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer. Nature Cell Biology, 2018, 20, 211-221.	4.6	98
160	Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy â€“ results from two independent randomized trials. Acta OncolÃ³gica, 2018, 57, 38-43.	0.8	22
161	A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Annals of Oncology, 2018, 29, 170-177.	0.6	84
162	Predictive model of complexity in early palliative care: a cohort of advanced cancer patients (PALCOM) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.6	27

#	Article	IF	Citations
163	Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies. Annals of Oncology, 2018, 29, viii61.	0.6	5
164	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clinical Cancer Research, 2018, 24, 5820-5829.	3.2	82
165	4th ESOâ€“ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology, 2018, 29, 1634-1657.	0.6	891
166	Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. Cancer Treatment Reviews, 2018, 67, 63-70.	3.4	79
167	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. Annals of Oncology, 2018, 29, 2121-2128.	0.6	74
168	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respiratory Medicine,the, 2018, 6, 771-781.	5.2	167
169	Molecular Tumor Boards. Breast Care, 2018, 13, 137-139.	0.8	2
170	PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial. European Journal of Cancer, 2018, 92, S117-S118.	1.3	5
171	Abstract P2-09-04: Association of intrinsic subtype and immune genes with pathological complete response in the OPTIHER-HEART phase II clinical trial following neoadjuvant trastuzumab/pertuzumab-based chemotherapy in HER2-positive breast cancer. , 2018, , .		2
172	Abstract P2-09-11: PAM50 intrinsic subtyping as a predictor of pathological complete response to neoadjuvant trastuzumab-based chemotherapy in early HER2-positive breast cancer. , 2018, , .		1
173	Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer. , 2018, , .		3
174	Abstract P4-04-05: Primary endocrine therapy (PETx) induces PAM50 intrinsic subtype migration with prognostic implications. , 2018, , .		2
175	Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC). Cancer Research, 2018, 78, PD3-06-PD3-06.	0.4	13
176	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. Journal of Clinical Investigation, 2018, 128, 3887-3905.	3.9	79
177	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.. Journal of Clinical Oncology, 2018, 36, 1025-1025.	0.8	3
178	Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2â€“) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial.. Journal of Clinical Oncology, 2018, 36, 1056-1056.	0.8	4
179	De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study.. Journal of Clinical Oncology, 2018, 36, 507-507.	0.8	6
180	HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.. Journal of Clinical Oncology, 2018, 36, 509-509.	0.8	10

#	Article	IF	Citations
181	SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR+ with or without letrozole) in trastuzumabâ€pretreated, postmenopausal patients with HER2â€positive metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, TPS1101-TPS1101.	0.8	5
182	A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318).. Journal of Clinical Oncology, 2018, 36, TPS3105-TPS3105.	0.8	2
183	Early safety from a phase 1, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected into liver tumors.. Journal of Clinical Oncology, 2018, 36, 438-438.	0.8	3
184	Different pCR rates according PAM50 defined subtypes in HER2 positive early breast cancer treated with neoadjuvant pertuzumab and trastuzumab.. Journal of Clinical Oncology, 2018, 36, e12634-e12634.	0.8	0
185	Immune-related expression profiles and sunitinib response in metastatic clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2018, 36, e16579-e16579.	0.8	1
186	Association between genotypes, clinical scores and survival outcome in metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 3553-3553.	0.8	2
187	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancers.. Journal of Clinical Oncology, 2018, 36, 3076-3076.	0.8	0
188	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. Clinical Cancer Research, 2017, 23, 649-657.	3.2	108
189	Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. Clinical and Translational Oncology, 2017, 19, 119-124.	1.2	23
190	Pertuzumab Use in the Adjuvant Setting: Why Not?. Journal of Clinical Oncology, 2017, 35, 1138-1138.	0.8	0
191	Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Nonâ€“Small-Cell Lung Cancer Patients. Clinical Chemistry, 2017, 63, 751-760.	1.5	62
192	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncology, The, 2017, 18, 545-554.	5.1	250
193	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. Cancer Research, 2017, 77, 2213-2221.	0.4	168
194	Immune-Related Gene Expression Profiling After PD-1 Blockade in Nonâ€“Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Research, 2017, 77, 3540-3550.	0.4	327
195	Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. Stem Cell Reports, 2017, 8, 1392-1407.	2.3	62
196	A PAM50-Based Chemoendocrine Score for Hormone Receptorâ€“Positive Breast Cancer with an Intermediate Risk of Relapse. Clinical Cancer Research, 2017, 23, 3035-3044.	3.2	28
197	GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. Cell Reports, 2017, 21, 2183-2197.	2.9	56
198	Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. British Journal of Cancer, 2017, 117, 1777-1786.	2.9	58

#	Article	IF	Citations
199	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast, 2017, 34, S19-S26.	0.9	46
200	miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway. Clinical Cancer Research, 2017, 23, 1091-1103.	3.2	114
201	Vasculitic neuropathy induced by pembrolizumab. Annals of Oncology, 2017, 28, 433-434.	0.6	36
202	Whatâ€™s New in Biology. Breast, 2017, 36, S29.	0.9	0
203	Abstract P1-09-09: Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer. , 2017, , .		3
204	Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC)â€•(GEICO 1205/NOVA TRIAL).. Journal of Clinical Oncology, 2017, 35, 5508-5508.	0.8	11
205	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. Oncotarget, 2017, 8, 21930-21937.	0.8	17
206	Intrinsic molecular subtypes of HER2+ breast cancer. Oncotarget, 2017, 8, 73362-73363.	0.8	34
207	Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. ESMO Open, 2016, 1, e000032.	2.0	7
208	Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. Annals of Oncology, 2016, 27, 1867-1873.	0.6	109
209	Prognostic Value of Intrinsic Subtypes in Hormone Receptorâ€“Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. JAMA Oncology, 2016, 2, 1287.	3.4	96
210	Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective study. Current Medical Research and Opinion, 2016, 32, 835-839.	0.9	6
211	Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. Breast Cancer Research and Treatment, 2016, 156, 81-89.	1.1	38
212	TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer. European Urology, 2016, 70, 709-713.	0.9	63
213	Home management of acute medical complications in cancer patients: a prospective pilot study. Supportive Care in Cancer, 2016, 24, 2129-2137.	1.0	9
214	Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. Bioinformatics, 2016, 32, 1097-1099.	1.8	255
215	Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. Clinical Cancer Research, 2016, 22, 560-566.	3.2	79
216	Tankyrase Inhibition Blocks Wnt/Î²-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clinical Cancer Research, 2016, 22, 644-656.	3.2	143

#	Article	IF	Citations
217	Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. Oncotarget, 2016, 7, 67956-67965.	0.8	4
218	Molecular Classification of Breast Cancer. , 2016, , 203-219.		2
219	High-risk ipilimumab-related diarrhea/colitis: Experience and use of ancillary tests in changing toxicity management.. Journal of Clinical Oncology, 2016, 34, e14552-e14552.	0.8	0
220	Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: A TCGA pan-cancer analysis.. Journal of Clinical Oncology, 2016, 34, 3033-3033.	0.8	0
221	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Medicine, 2015, 13, 303.	2.3	113
222	Gene expressionâ€based classifications of fibroadenomas and phyllodes tumours of the breast. Molecular Oncology, 2015, 9, 1081-1090.	2.1	39
223	PG 3.01 Clinical implications of the intrinsic molecular subtypes. Breast, 2015, 24, S5-S6.	0.9	4
224	Response. Journal of the National Cancer Institute, 2015, 107, djv029-djv029.	3.0	0
225	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptorâ€“positive breast cancer. Science Translational Medicine, 2015, 7, 283ra51.	5.8	276
226	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. Oncologist, 2015, 20, 474-482.	1.9	145
227	Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer. Current Medical Research and Opinion, 2015, 31, 1129-1137.	0.9	37
228	Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast, 2015, 24, S26-S35.	0.9	735
229	Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. Journal of the National Cancer Institute, 2015, 107, djv256.	3.0	90
230	Chemotherapy benefit for â€˜ER-positiveâ€™ breast cancer and contamination of Nonluminal subtypesâ€”waiting for TAILORx and RxPONDER. Annals of Oncology, 2015, 26, 70-74.	0.6	11
231	SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene, 2015, 34, 671-680.	2.6	72
232	Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma.. Journal of Clinical Oncology, 2015, 33, 9069-9069.	0.8	15
233	PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer.. Journal of Clinical Oncology, 2015, 33, TPS642-TPS642.	0.8	1
234	Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. Oncotarget, 2015, 6, 28173-28182.	0.8	34

#	Article	IF	Citations
235	Prosigna (PAM50) to predict response to neoadjuvant chemotherapy (NAC) in HR+/HER2- early breast cancer (EBC) patients.. Journal of Clinical Oncology, 2015, 33, 11049-11049.	0.8	2
236	Blinded independent validation of the PAM50-based Chemo-Endocrine Sensitivity Predictor (CESP) in hormone receptor (HR)-positive/HER2-negative (HR+/HER2-) breast cancer following neoadjuvant chemotherapy (NAC).. Journal of Clinical Oncology, 2015, 33, 569-569.	0.8	0
237	Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Annals of Oncology, 2014, 25, 552-563.	0.6	290
238	Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	178
239	Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. Journal of the National Cancer Institute, 2014, 106, .	3.0	36
240	Differentiation and Loss of Malignant Character of Spontaneous Pulmonary Metastases in Patient-Derived Breast Cancer Models. Cancer Research, 2014, 74, 7406-7417.	0.4	37
241	Age-Specific Changes in Intrinsic Breast Cancer Subtypes: A Focus on Older Women. Oncologist, 2014, 19, 1076-1083.	1.9	122
242	Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patientâ€™s management and therapy selection. Clinical and Translational Oncology, 2014, 16, 386-394.	1.2	19
243	Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. Clinical and Experimental Metastasis, 2014, 31, 33-45.	1.7	46
244	Potential biomarkers of longâ€term benefit from singleâ€agent trastuzumab or lapatinib in HER2â€positive metastatic breast cancer. Molecular Oncology, 2014, 8, 20-26.	2.1	37
245	Predicting response and survival in chemotherapy-treated triple-negative breast cancer. British Journal of Cancer, 2014, 111, 1532-1541.	2.9	100
246	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Research and Treatment, 2014, 146, 557-566.	1.1	59
247	Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status. Breast Cancer Research and Treatment, 2014, 147, 185-191.	1.1	37
248	How Many Etiological Subtypes of Breast Cancer: Two, Three, Four, Or More?. Journal of the National Cancer Institute, 2014, 106, dju165-dju165.	3.0	191
249	Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer, 2014, 14, 302.	1.1	49
250	Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study. Clinical Cancer Research, 2014, 20, 511-521.	3.2	191
251	Cell-State Transitions Regulated by SLUG Are Critical for Tissue Regeneration and Tumor Initiation. Stem Cell Reports, 2014, 2, 633-647.	2.3	85
252	The Hippo Transducer TAZ Interacts with the SWI/SNF Complex to Regulate Breast Epithelial Lineage Commitment. Cell Reports, 2014, 6, 1059-1072.	2.9	139

#	Article	IF	Citations
253	PELO negatively regulates HER receptor signalling and metastasis. Oncogene, 2014, 33, 1190-1197.	2.6	13
254	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. Journal of Clinical Investigation, 2014, 124, 1418-1418.	3.9	0
255	Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Research and Treatment, 2013, 142, 237-255.	1.1	169
256	Prognostic Significance of Progesterone Receptorâ€“Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer. Journal of Clinical Oncology, 2013, 31, 203-209.	0.8	464
257	MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Research and Treatment, 2013, 137, 373-382.	1.1	90
258	Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts. Cell Reports, 2013, 4, 1116-1130.	2.9	539
259	MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nature Communications, 2013, 4, 1393.	5.8	209
260	PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Research and Treatment, 2013, 138, 457-466.	1.1	96
261	Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice. Clinical Cancer Research, 2013, 19, 4889-4899.	3.2	56
262	Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade and Hormonal Therapy for the Treatment of Primary HER2-Positive Breast Cancer: One More Step Toward Chemotherapy-Free Therapy. Journal of Clinical Oncology, 2013, 31, 1703-1706.	0.8	25
263	Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer. Oncologist, 2013, 18, 123-133.	1.9	454
264	Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1301-E1310.	3.3	61
265	SWI/SNF Chromatin-Remodeling Factor Smarcd3/Baf60c Controls Epithelial-Mesenchymal Transition by Inducing Wnt5a Signaling. Molecular and Cellular Biology, 2013, 33, 3011-3025.	1.1	54
266	A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells. Clinical Cancer Research, 2013, 19, 6787-6801.	3.2	80
267	A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models. Cancer Research, 2013, 73, 4885-4897.	0.4	394
268	Reply to Y. Yamamoto et al. Journal of Clinical Oncology, 2013, 31, 2517-2518.	0.8	2
269	Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Scientific Reports, 2013, 3, 3544.	1.6	45
270	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. Journal of Clinical Investigation, 2013, 123, 2551-2563.	3.9	108

#	Article	IF	Citations
271	ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. Journal of Clinical Investigation, 2013, 123, 4329-4343.	3.9	49
272	Abstract LB-265: Patient-derived xenografts from advanced luminal-type breast cancer: insights into endocrine therapy resistance.. , 2013, , .		0
273	Abstract 4452: p90RSK mediates resistance to PI3K-pathway inhibitors in breast cancer.. , 2013, , .		0
274	Protein tyrosine kinase 6 (PTK6, BRK) amplification in HER2+ breast cancer as a mechanism of HER2 resistance.. Journal of Clinical Oncology, 2013, 31, 11021-11021.	0.8	0
275	Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Annals of Oncology, 2012, 23, 2866-2873.	0.6	123
276	The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 221-226.	3.3	64
277	Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. British Journal of Cancer, 2012, 107, 1249-1256.	2.9	62
278	PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Research and Treatment, 2012, 135, 301-306.	1.1	156
279	Defining the cellular precursors to human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2772-2777.	3.3	185
280	PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition. Cancer Discovery, 2012, 2, 1036-1047.	7.7	507
281	PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers. BMC Medical Genomics, 2012, 5, 44.	0.7	250
282	Comprehensive molecular portraits of human breast tumours. Nature, 2012, 490, 61-70.	13.7	10,282
283	USP15 stabilizes TGF-Î² receptor I and promotes oncogenesis through the activation of TGF-Î² signaling in glioblastoma. Nature Medicine, 2012, 18, 429-435.	15.2	342
284	Practical implications of gene-expression-based assays for breast oncologists. Nature Reviews Clinical Oncology, 2012, 9, 48-57.	12.5	242
285	Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Research and Treatment, 2012, 132, 523-535.	1.1	189
286	Lunatic Fringe Deficiency Cooperates with the Met/Caveolin Gene Amplicon to Induce Basal-like Breast Cancer. Cancer Cell, 2012, 21, 626-641.	7.7	113
287	Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. Journal of Clinical Investigation, 2012, 122, 1541-1552.	3.9	187
288	Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG.. Journal of Clinical Oncology, 2012, 30, 1008-1008.	0.8	14

#	Article	IF	Citations
289	Gene expression-based predictors of chemotherapy response in basal-like breast cancer.. Journal of Clinical Oncology, 2012, 30, 10500-10500.	0.8	2
290	Molecular classification of triple-negative tumors. Breast Cancer Research, 2011, 13, .	2.2	0
291	Deconstructing the molecular portraits of breast cancer. Molecular Oncology, 2011, 5, 5-23.	2.1	1,059
292	MAP3K4/CBP-Regulated H2B Acetylation Controls Epithelial-Mesenchymal Transition in Trophoblast Stem Cells. Cell Stem Cell, 2011, 8, 525-537.	5.2	102
293	Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Research, 2011, 13, R125.	2.2	87
294	Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptorâ€“Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtypeâ€”ACOSOG Z1031. Journal of Clinical Oncology, 2011, 29, 2342-2349.	0.8	470
295	Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Medical Genomics, 2011, 4, 3.	0.7	142
296	Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. BMC Medical Genomics, 2011, 4, 77.	0.7	38
297	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 ⁺ breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3761-3766.	3.3	291
298	S5-2: PAM50 HER2â^'Enriched Subtype Enriches for Tumor Response to Neoadjuvant Anthracyclines/Taxane and Trastuzumab/Taxane Containing Regimens in HER2â^'Positive Breast Cancer.. , 2011, , .		2
299	Concordance among gene-expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.. Journal of Clinical Oncology, 2011, 29, 502-502.	0.8	3
300	Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis.. Journal of Clinical Oncology, 2011, 29, 529-529.	0.8	10
301	Abstract 3328: Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. , 2011, , .		1
302	Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncology, The, 2010, 11, 718-719.	5.1	92
303	Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research, 2010, 12, R68.	2.2	1,748
304	Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. Annals of Oncology, 2009, 20, 294-297.	0.6	32
305	Mammary development meets cancer genomics. Nature Medicine, 2009, 15, 842-844.	15.2	171
306	Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with secondâ€“third line erlotinib. Lung Cancer, 2009, 66, 257-261.	0.9	16

#	Article	IF	Citations
307	Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy.. , 2009, , .		13
308	Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumabâ€based therapy. Head and Neck, 2008, 30, 680-683.	0.9	87
309	Update on novel therapeutic agents for cervical cancer. Gynecologic Oncology, 2008, 110, S72-S76.	0.6	59
310	Acute severe hypothyroidism induced by sunitinib. Radiotherapy and Oncology, 2008, 89, 124-125.	0.3	2
311	Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Annals of Oncology, 2008, 19, 327-331.	0.6	54
312	Prognostic Role of CA-125 Nadir in Stage IV Epithelial Ovarian Cancer. Journal of Clinical Oncology, 2008, 26, 1771-1772.	0.8	4
313	The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nature Clinical Practice Oncology, 2008, 5, 531-542.	4.3	153
314	A Rare Case of Malignant Solitary Fibrous Tumor of the Spinal Cord. Spine, 2008, 33, E397-E399.	1.0	52
315	Hepatic Pneumatosis As a Complication of an Abdominal Desmoid Tumor. Journal of Clinical Oncology, 2007, 25, 897-898.	0.8	4
316	160 INVITED Biopsy-driven biomarker development: pharmacodynamic studies in early clinical trials. European Journal of Cancer, Supplement, 2007, 5, 43-44.	2.2	0
317	Acute Lung Injury Associated with Docetaxel and Bevacizumab. Clinical Oncology, 2007, 19, 803-805.	0.6	14
318	New approaches in angiogenic targeting for colorectal cancer. World Journal of Gastroenterology, 2007, 13, 5857.	1.4	50
319	Validation of CA-125 concentration nadir within the normal range following primary treatment as a predictor of survival for epithelial ovarian cancer (EOC). Journal of Clinical Oncology, 2007, 25, 16007-16007.	0.8	0